NSGC 2026: Ambry's Whole Genome Sequencing and BillionToOne's Unity Confirm

NSGC 2026: Ambry's Whole Genome Sequencing and BillionToOne's Unity Confirm

Title history
  • NSGC 2026: Ambry's Whole Genome Sequencing and BillionToOne's Unity Confirm — observed on 20261115-2208 UTC (YouTube)
🎙 Kira Dineen (DNA Today) 👥 4K 📅 November 15, 2026 ⏱ 31 min 👁 1 📄 expert opinion 🧭 2026-11-15
Available in: English (current) Français

Keywords

whole genome sequencingRNA analysispangenomeUnity Confirmprenatal diagnostics

Summary

This episode of DNA Today, recorded live at the National Society of Genetic Counselors (NSGC) 2026 Annual Conference in Baltimore, features two interview segments. The first, with Dr. Thomas (TJ) Slavin, Chief Medical Officer of Ambry Genetics, discusses the launch of whole genome sequencing products GenomeNext and GenomeReveal. Key topics include the integration of RNA analysis to clarify variants of uncertain significance, the use of a human pangenome reference to improve variant detection across diverse ancestries, and the proactive reanalysis program ‘Patient for Life’ which has led to additional diagnoses in about 4% of cases. The second segment with Jennifer (Jen) Hoskovec, Vice President of Medical Affairs at BillionToOne, introduces Unity Confirm, a cell-based prenatal testing option that isolates intact extravillous trophoblasts from maternal blood to provide additional information after high-risk NIPT results. The discussion covers how this technology differs from traditional cell-free DNA screening, its positioning as a supplemental option rather than a replacement for invasive diagnostic procedures, and the challenges of analyzing small cell numbers, including placental mosaicism. The episode also celebrates Genetic Counselor Appreciation Day and acknowledges Kira Dineen’s receipt of the NSGC Leader in Community Engagement Award.

191 words

Critical Evaluation

Value of the Information & Strength of the Argument

The interviews provide valuable insights into emerging genetic testing technologies and their potential clinical impact. The discussion on both Ambry’s whole genome sequencing and BillionToOne’s Unity Confirm is well-structured, with guests clearly explaining technical aspects and practical applications. The arguments for adopting these tests are based on clinical needs, such as reducing diagnostic odysseys and bridging gaps in prenatal care. However, the reasoning is primarily company-led, with limited critical appraisal of limitations or comparison with existing methods. The value lies in the up-to-date information and expert perspectives, though the argumentation would benefit from more independent evidence or acknowledgment of potential drawbacks.

Scientific Rigor, Source Quality, Title Accuracy

The video maintains a professional level of scientific rigor, with guests citing real-world data (e.g., 8% diagnostic lift from WGS, 4% dual diagnoses) and referencing established concepts like the pangenome. However, no direct citations of peer-reviewed studies are provided in the transcript, and the sources mentioned are limited to the episode’s resource page on DNAtoday.com. The title is appropriately descriptive and aligns well with the content; no significant imbalance between title and coverage is noted. The absence of external citations reduces the overall rigor, but the credibility of the speakers and the specificity of technical details partially mitigate this.

215 words

Title / Content Match

The title accurately reflects the content: two interview segments covering Ambry's whole genome sequencing and BillionToOne's Unity Confirm, both presented at the NSGC 2026 conference.

Quality & Reliability

7/10

The video features expert interviews with medical professionals from two companies, offering insights into new genetic tests, but relies largely on company claims without independent validation. The clinical relevance is high, yet the content is partly promotional and not peer-reviewed.

Key Moments

Cited Sources

  • DNA Today Episode 420 — The episode's resource page, as mentioned in the description, provides links to further information and related materials.

Contribution & Novelties

The episode provides an early look at two significant advances in genetic testing unveiled at NSGC 2026: Ambry’s integration of whole genome sequencing with RNA analysis and pangenome references, and BillionToOne’s Unity Confirm test using intact fetal cells. It offers practical context for genetic counselors about how these technologies might be incorporated into patient care, including addressing disparities and providing non-invasive options after high-risk NIPT results. The discussions highlight the proactive reanalysis approach and the potential for dual diagnoses, which are not widely covered in mainstream media.

Pour aller plus loin :

  • Whole genome sequencing — Background on the technology and its applications.
  • Pangenome — Explanation of the pangenome reference and its role in capturing human genetic diversity.
  • RNA splicing — Key process relevant to interpreting splice-altering variants.
  • Noninvasive prenatal testing — Overview of NIPT and its limitations, context for cell-based alternatives.

142 words

Radar Profile

The radar profile shows a balanced performance, with moderate-to-high scores in quantity and level of technical detail, but slightly lower quality and reliability due to reliance on company representatives and absence of independent verification. The overall shape suggests a solid informational piece with room for more rigorous sourcing.

Reliability 6/10